Eyevensys Names Ronald Buggage as Chief Medical Officer

September 8, 2017: By Jon Swedien

eyevensysEyevensys has appointed Ronald Buggage, MD, its chief medical officer, the French company announced Sept. 4.

Eyevensys is a private clinical stage biotech company based in Paris. The company is developing its proprietary EyeCET platform, which it says is the first non-viral gene expression technology that enables safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.

Buggage will drive the company’s drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based on the EyeCET platform.

Buggage was most recently division medical officer at Sanofi’s Ophthalmology Unit, Eyevensys said. He was responsible for coordination of medical and scientific activities for Sanofi’s ophthalmology portfolio, including development programs for ocular gene therapy.

He has also served as chief scientific officer at Novagali Pharma, where he was responsible for the global clinical and regulatory strategy.

Buggage has also held positions in clinical development at Novartis and Pfizer. He obtained his doctorate at the UCLA School of Medicine and specialized in ophthalmology at Emory University. He completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022